File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Chemoradiation and adjuvant chemotherapy in cervical cancer

TitleChemoradiation and adjuvant chemotherapy in cervical cancer
Authors
Issue Date1999
PublisherAmerican Society of Clinical Oncology. The Journal's web site is located at http://www.jco.org/
Citation
Journal Of Clinical Oncology, 1999, v. 17 n. 7, p. 2055-2060 How to Cite?
AbstractPurpose: Radiotherapy is the standard treatment for locally advanced cervical cancer, but treatment results remain disappointing, particularly for women with bulky central disease. We investigated the role of concurrent chemoradiation and adjuvant chemotherapy in a randomized trial. Patients and Methods: Two hundred twenty patients with bulky stage I, II, and III cervical cancer were randomized to receive either standard pelvic radiotherapy or chemoradiation (epirubicin 60 mg/m 2) followed by adjuvant chemotherapy with epirubicin 90 mg/m 2 administered at 4-week intervals for five additional cycles. Results: Fifty-nine patients have relapsed, with a median follow-up duration of 77 months. Patients who received epirubicin radiation therapy showed a significantly longer disease-free (P = .03) and cumulative survival (P = .04). Patients who received radiation alone had significantly more distant metastasis than those who received chemoradiation (P = .012). There was no difference in long-term local tumor control (P = .99). Conclusion: Survival benefit has been demonstrated in patients treated with chemoradiation followed by adjuvant chemotherapy with epirubicin as compared with patients treated with standard pelvic radiotherapy alone.
Persistent Identifierhttp://hdl.handle.net/10722/87181
ISSN
2015 Impact Factor: 20.982
2015 SCImago Journal Rankings: 9.204
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorWong, LCen_HK
dc.contributor.authorNgan, HYSen_HK
dc.contributor.authorCheung, ANYen_HK
dc.contributor.authorCheng, DKLen_HK
dc.contributor.authorNg, TYen_HK
dc.contributor.authorChoy, DTKen_HK
dc.date.accessioned2010-09-06T09:26:22Z-
dc.date.available2010-09-06T09:26:22Z-
dc.date.issued1999en_HK
dc.identifier.citationJournal Of Clinical Oncology, 1999, v. 17 n. 7, p. 2055-2060en_HK
dc.identifier.issn0732-183Xen_HK
dc.identifier.urihttp://hdl.handle.net/10722/87181-
dc.description.abstractPurpose: Radiotherapy is the standard treatment for locally advanced cervical cancer, but treatment results remain disappointing, particularly for women with bulky central disease. We investigated the role of concurrent chemoradiation and adjuvant chemotherapy in a randomized trial. Patients and Methods: Two hundred twenty patients with bulky stage I, II, and III cervical cancer were randomized to receive either standard pelvic radiotherapy or chemoradiation (epirubicin 60 mg/m 2) followed by adjuvant chemotherapy with epirubicin 90 mg/m 2 administered at 4-week intervals for five additional cycles. Results: Fifty-nine patients have relapsed, with a median follow-up duration of 77 months. Patients who received epirubicin radiation therapy showed a significantly longer disease-free (P = .03) and cumulative survival (P = .04). Patients who received radiation alone had significantly more distant metastasis than those who received chemoradiation (P = .012). There was no difference in long-term local tumor control (P = .99). Conclusion: Survival benefit has been demonstrated in patients treated with chemoradiation followed by adjuvant chemotherapy with epirubicin as compared with patients treated with standard pelvic radiotherapy alone.en_HK
dc.languageengen_HK
dc.publisherAmerican Society of Clinical Oncology. The Journal's web site is located at http://www.jco.org/en_HK
dc.relation.ispartofJournal of Clinical Oncologyen_HK
dc.subject.meshAdulten_HK
dc.subject.meshAntibiotics, Antineoplastic - therapeutic useen_HK
dc.subject.meshChemotherapy, Adjuvant - methodsen_HK
dc.subject.meshCombined Modality Therapy - methodsen_HK
dc.subject.meshDisease-Free Survivalen_HK
dc.subject.meshEpirubicin - therapeutic useen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshHong Kong - epidemiologyen_HK
dc.subject.meshHumansen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshRadiotherapy - methodsen_HK
dc.subject.meshSurvival Rateen_HK
dc.subject.meshUterine Cervical Neoplasms - drug therapy - mortality - radiotherapyen_HK
dc.titleChemoradiation and adjuvant chemotherapy in cervical canceren_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0732-183X&volume=17&issue=7&spage=2055&epage=2060&date=1999&atitle=Chemoradiation+and+adjuvant+chemotherapy+in+cervical+canceren_HK
dc.identifier.emailNgan, HYS:hysngan@hkucc.hku.hken_HK
dc.identifier.emailCheung, ANY:anycheun@hkucc.hku.hken_HK
dc.identifier.authorityNgan, HYS=rp00346en_HK
dc.identifier.authorityCheung, ANY=rp00542en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.pmid10561258-
dc.identifier.scopuseid_2-s2.0-0033023214en_HK
dc.identifier.hkuros50091en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0033023214&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume17en_HK
dc.identifier.issue7en_HK
dc.identifier.spage2055en_HK
dc.identifier.epage2060en_HK
dc.identifier.isiWOS:000081264300015-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridWong, LC=7402092003en_HK
dc.identifier.scopusauthoridNgan, HYS=34571944100en_HK
dc.identifier.scopusauthoridCheung, ANY=54927484100en_HK
dc.identifier.scopusauthoridCheng, DKL=7402806161en_HK
dc.identifier.scopusauthoridNg, TY=7402229853en_HK
dc.identifier.scopusauthoridChoy, DTK=7102939127en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats